Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
John Dixon
John Dixon, Singapore SG
| Patent application number | Description | Published |
|---|---|---|
| 20100311077 | Use of GPR100 Receptor in Diabetes and Obesity Regulation - We describe a method of identifying a molecule suitable for the treatment, prophylaxis or alleviation of a Gpr100 associated disease, in particular diabetes and obesity, the method comprising determining whether a candidate molecule is an agonist or antagonist of Gpr100 polypeptide, in which the Gpr100 polypeptide comprises the amino acid sequence shown in SEQ ID NO: 3 or SEQ ID NO: 5, or a sequence which is at least 90% identical thereto. | 12-09-2010 |
John Dixon, Cambridgeshire GB
| Patent application number | Description | Published |
|---|---|---|
| 20100158807 | RECEPTOR - We disclose a method of treating or preventing a disease selected from the group consisting of: a bladder disease, a bladder disorder, benign prostatic hyperplasia, bladder outlet obstruction, incontinence, including overflow and urge incontinence, urinary urge, cystitis, including interstitial cystitis and overactive bladder. | 06-24-2010 |
| 20100272647 | RECEPTOR - We disclose BACH G-protein coupled receptor (GPCR) polypeptides comprising the amino acid sequence shown in SEQ ID NO. 3 or SEQ ID NO: 5, and homologues, variants and derivatives thereof Nucleic acids capable of encoding BACH polypeptide are also disclosed, in particular, those comprising the nucleic acid sequences shown in SEQ ID No. 1, SEQ ID No.2 or SEQ ID NO: 4 or a mouse BACH genomic sequence (SEQ ID NO: 10). | 10-28-2010 |
John Dixon, Van Nuys, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20100068854 | MEMS Switch Capping and Passivation Method - A MEMS switch with a platinum-series contact is capped through a process that also passivates the contact by controlling, over time, the amount of oxygen in the environment, pressures and temperatures. Some embodiments passivate a contact in an oxygenated atmosphere at a first temperature and pressure, before hermetically sealing the cap at a higher temperature and pressure. Some embodiments hermetically seal the cap at a temperature below which passivating dioxides will form, thus trapping oxygen within the volume defined by the cap, and later passivate the contact with the trapped oxygen at a higher temperature. | 03-18-2010 |
John Dixon, Moss Beach, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20100003765 | METHODS AND SYSTEMS FOR MITIGATING OXYGEN ENHANCED DAMAGE IN REAL-TIME ANALYTICAL OPERATIONS - Methods and systems for performing analytical reactions under reduced or non-oxygen conditions, where such reactions are potentially subject to damaging effects of oxygen, including particularly fluorescent based detection methods where fluorescent species may be prone to generation of reactive oxygen species. | 01-07-2010 |
John Dixon, The Impezial SG
| Patent application number | Description | Published |
|---|---|---|
| 20090187996 | Ion Channel - The present invention relates to a method of identifying a molecule suitable for the treatment, prophylaxis or alleviation of pain, the method comprising determining whether a candidate molecule is an agonist or antagonist, including a opener, blocker or modulator, of Kv9.2 polypeptide, in which the Kv9.2 polypeptide comprises the amino acid sequence shown in SEQ ID NO:3 or SEQ ID NO:5, or a sequence which is at least 90% identical thereto. | 07-23-2009 |
John Dixon, Cambridge GB
| Patent application number | Description | Published |
|---|---|---|
| 20080269118 | Use of Gpr100 receptor in diabetes and obesity regulation - We describe a method of identifying a molecule suitable for the treatment, prophylaxis or alleviation of a Gpr100 associated disease, in particular diabetes and obesity, the method comprising determining whether a candidate molecule is an agonist or antagonist of Gpr100 polypeptide, in which the Gpr100 polypeptide comprises the amino acid sequence shown in SEQ ID NO: 3 or SEQ ID NO: 5, or a sequence which is at least 90% identical thereto. | 10-30-2008 |
| 20090036394 | GRP 146 Receptor - We disclose GPR146 G-protein coupled receptor (GPCR) polypeptides comprising the amino acid sequence shown in SEQ ID NO. 3 or SEQ ID NO: 5, and homologues, variants and derivatives thereof. Nucleic acids capable of encoding GPR146 polypeptide are also disclosed, in particular, those comprising the nucleic acid sequences shown in SEQ ID No. 1A, SEQ ID No.1 B, SEQ ID No.2 or SEQ ID NO: 4. The GPR146 receptor is useful in the diagnosis and therapy of dyslipidaemias. | 02-05-2009 |
| 20090048200 | GPR 26 G-Protein Coupled Receptor - We disclose GPR26 G-protein coupled receptor (GPCR) polypeptides comprising the amino acid sequence shown in SEQ ID NO. 3 or SEQ ID NO: 5, and homologues, variants and derivatives thereof. Nucleic acids capable of encoding GPR26 polypeptide are also disclosed. The GPR26 receptor is useful in the diagnosis and therapy of mental illness. | 02-19-2009 |